[1]Luetke A,Meyers PA,Lewis I,et al.Osteosarcoma treatment-Where do we stand? A state of the art review. Cancer Treatt Rev.2013;40(4):523-532.[2]Tacar O,Sriamornsak P,Dass CR.Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.J Pharm Pharmacol.2013;65(2):157-170.[3]Seow HF,Yip WK,Fifis T.Advances in targeted and immunobased therapies for colorectal cancer in the genomic era.Onco Targets Ther.2016;9:1899-1920.[4]Melero I,Berman DM,Aznar MA,et al.Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer.2015;15(8):457-472.[5]Galluzzi L,Buque A,Kepp O,et al.Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell.2015;28(6):690-714.[6]Chou YS,Yen CC,Chen WM,et al.Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest,apoptosis,cellular senescence,and synergistic effect with paclitaxel.Int J Oncol.2016;48(3):1187-1194.[7]Ma H,He C,Cheng Y,et al.PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment.Biomaterials. 2014;35(30): 8723-8734.[8]Gjertsen BT,Schoffski P.Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia.2015;29(1):11-19.[9]Cheng L,Wang C,Jing J. Polo-like kinase 1 as a potential therapeutic target for osteosarcoma.Curr Pharm Des.2015; 21(10):1347-1350.[10]Zhao L,Jiang BO,Wang D,et al.Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression.Exp Ther Med.2016;11(5):2005-2010. [11]姚琴,赵慧毅,谢柏臻.Ezrin shRNA联合HSP70对骨肉瘤细胞凋亡和增殖的影响[J].中华骨科杂志,2015, 35(2):165-173.[12]Mathuriya AS.Magnetotactic bacteria: nanodrivers of the future.Crit RevBiotechnol. 2015;22(6):1-15.[13]Goldhawk DE,Gelman N,Thompson RT,et al.Forming Magnetosome-Like Nanoparticles in Mammalian Cells for Molecular MRI[M]//Design and Applications of Nanoparticles in Biomedical Imaging.Springer International Publishing, 2017:187-203.[14]张薇薇,许乙凯,刘瑞源.基于趋磁细菌磁小体的新型主动靶向线粒体的MR双功能探针制备[J].中华放射学杂志, 2014,48(6): 509-511.[15]Chen CY,Chen CF,Yong Y,et al.Construction of a microrobot system using magnetotactic bacteria for the separation of Staphylococcus aureus.Biomed Microdevices. 2014;16(5): 761-770. [16]Alphandéry E,Guyot F,Chebbi I.Preparation of chains of magnetosomes, isolated from Magnetospirillum magneticum, strain AMB-1 magnetotactic bacteria, yielding efficient treatment of tumors using magnetic hyperthermia.Int J Pharm. 2012;434(1-2):444-452.[17]Yuan-Gang L,Qing-Lei D,Shi-Bin W,et al.Preparation and in vitro antitumor effects of cytosine arabinoside-loaded genipin-poly-l-glutamic acid-modified bacterial magnetosomes. Int J Nanomedicine. 2015;10:1387-1397.[18]Isakoff MS,Bielack SS,Meltzer P,et al.Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.J Clin Oncol.2015;33(27):3029-3035.[19]Gill J,Ahluwalia MK,Geller D,et al.New targets and approaches in osteosarcoma.Pharmacol Ther. 2013;137(1): 89-99.[20]Teagle AR,Birchall JC,Hargest R.Gene Therapy for Pyoderma Gangrenosum: Optimal Transfection Conditions and Effect of Drugs on Gene Delivery in the HaCaT Cell Line Using Cationic Liposomes.Skin Pharmacol Physiol. 2016;29(3): 119-129.[21]Lohße A,Ullrich S,Katzmann E,et al.Functional Analysis of the Magnetosome Island in Magnetospirillum gryphiswaldense: The mamAB Operon Is Sufficient for Magnetite Biomineralization. Plos One.2011;6(10):e25561.[22]Alphandéry E,Chebbi I,Guyot F,et al.Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumours: A review.Int J Hyperthermia.2013;29(8):801.[23]Hervault A,Dunn AE,Lim M,et al.Doxorubicin loaded dual pH-and thermo-responsive magnetic nanocarrier for combined magnetic hyperthermia and targeted controlled drug delivery applications. Nanoscale.2016;8(24):12152.[24]Sun J,Li Y,Liang XJ,et al.Bacterial magnetosome: a novel biogenetic magnetic targeted drug carrier with potential multifunctions.J Nanomater. 2011;2011(2011):469031- 469043.[25]王熙,耿圆圆,侯蔷,等.细菌磁小体作为新型非病毒载体用于肿瘤基因治疗的研究进展[J].肿瘤学杂志, 2016,22(4):322-326.[26]尹燕鹰,顾宁,洪敏,等.靶向磁性热疗对小鼠结肠癌皮下移植模型作用的观察[J].中华肿瘤防治杂志,2013, 20(4):249-253.[27]Li C,Ke Y,Yu S,et al.Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy.Int J Nanomedicine. 2016;11:5277-5286.[28]Sero V,Tavanti E,Vella S,et al.Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.Invest New Drugs.2014; 32(6):1167-1180.[29]Otsu H,Iimori M,Ando K,et al.Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis.Oncology.2016;2(6):15-16.[30]Fischer M,Quaas M,Nickel A,et al.Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.Oncotarget.2015;6(39):41402-41417.[31]Ogawa R,Morii A,Watanabe A,et al.Regulation of gene expression in human prostate cancer cells with artificially constructed promoters that are activated in response to ultrasound stimulation.Ultrason Sonochem.2012;20(1): 460-467.[32]Bhayani KR,Rajwade JM,Paknikar KM.Radio frequency induced hyperthermia mediated by dextran stabilized LSMO nanoparticles: in vitro evaluation of heat shock protein response. Nanotechnology.2013;24(1):015102.[33]Yamaguchi M,Ito A,Okamoto N,et al.Heat-inducible transgene expression system incorporating a positive feedback loop of transcriptional amplification for hyperthermia-induced gene therapy.J Biosci Bioeng.2012;114(4):460-465.[34]Yamaguchi M,Ito A,Ono A,et al.Heat-inducible gene expression system by applying alternating magnetic field to magnetic nanoparticles.ACS Synth Biol 2014;3(5):273-279.[35]Tantos A,Kalmar L,Tompa P.The role of structural disorder in cell cycle regulation, related clinical proteomics, disease development and drug targeting.Expert Rev Proteomics.2015; 12(3):221-233.[36]Liu Y,Bi T,Dai W,et al.Lupeol Induces Apoptosis and Cell Cycle Arrest of Human Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway.TechnolCancer Res Treat.2016; 15(6):NP16. |